Innate Pharma Tangible Net Worth Ratio
Innate Pharma tangible net worth ratio. Innate Pharma (IPHA) has a Tangible Net Worth Ratio of 100.0% as of June 2025. This metric is calculated by deducting intangible assets ($0.00) from net assets ($5.14 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Check Innate Pharma strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Innate Pharma (2005–2024)
Tangible net worth ratio of Innate Pharma from 2005 to 2024. This chart shows how Innate Pharma's Tangible Net Worth Ratio has changed across 20 annual periods from 2005 to 2024. As of June 2025, the ratio stands at 100.0%, reflecting net assets of $5.14 Million with intangible assets of $0.00 USD. See IPHA current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Innate Pharma Tangible Net Worth Ratio by Year (2005–2024)
Innate Pharma tangible net worth ratio by year from 2005 to 2024. The table below presents the year-by-year Tangible Net Worth Ratio for Innate Pharma from 2005 to 2024, covering 20 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see IPHA market cap overview.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 100.0% | $8.83 Million | $0.00 | $111.06 Million | ▲ +1.0 pp |
| 2023 | 99.0% | $42.90 Million | $416.00K | $175.19 Million | ▲ +77.6 pp |
| 2022 | 21.4% | $54.15 Million | $42.55 Million | $207.86 Million | ▼ -37.5 pp |
| 2021 | 58.9% | $107.44 Million | $44.19 Million | $267.50 Million | ▼ -11.5 pp |
| 2020 | 70.3% | $155.97 Million | $46.29 Million | $307.42 Million | ▲ +14.9 pp |
| 2019 | 55.4% | $217.42 Million | $96.97 Million | $401.36 Million | ▲ +5.9 pp |
| 2018 | 49.5% | $167.24 Million | $84.53 Million | $451.22 Million | ▲ +3.2 pp |
| 2017 | 46.3% | $85.96 Million | $46.19 Million | $255.02 Million | ▼ -43.2 pp |
| 2016 | 89.5% | $86.17 Million | $9.07 Million | $281.58 Million | ▲ +3.0 pp |
| 2015 | 86.5% | $72.07 Million | $9.73 Million | $305.96 Million | ▼ -6.3 pp |
| 2014 | 92.8% | $74.63 Million | $5.36 Million | $90.69 Million | ▼ -7.2 pp |
| 2013 | 100.0% | $40.29 Million | $0.00 | $55.88 Million | ▲ +0.0 pp |
| 2012 | 100.0% | $23.36 Million | $0.00 | $48.30 Million | ▲ +0.0 pp |
| 2011 | 100.0% | $26.62 Million | $0.00 | $60.11 Million | ▲ +0.0 pp |
| 2010 | 100.0% | $33.52 Million | $0.00 | $48.01 Million | ▲ +0.0 pp |
| 2009 | 100.0% | $47.12 Million | $0.00 | $64.22 Million | ▲ +0.0 pp |
| 2008 | 100.0% | $41.34 Million | $0.00 | $60.86 Million | ▲ +0.0 pp |
| 2007 | 100.0% | $49.61 Million | $0.00 | $63.15 Million | ▲ +0.0 pp |
| 2006 | 100.0% | $56.37 Million | $0.00 | $69.25 Million | ▲ +0.0 pp |
| 2005 | 100.0% | $20.07 Million | $0.00 | $24.77 Million | — |